Paper Details

  1. Home
  2. Paper Details

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.

Author: Abou-AlfaGhassan K, Al-RajabiRaed, BoradMitesh J, CatenacciDaniel V, DotanEfrat, FélizLuis, GallinsonDavid, HollebecqueAntoine, JiTao, LihouChristine F, MelisiDavide, MurphyAdrian G, OhDo-Youn, PaulsonAndrew S, SahaiVaibhav, VaccaroGina, Van CutsemEric, VogelArndt, ZhenHuiling

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the safety and antitumor activity of pemigatinib, a selective FGFR inhibitor, in patients with previously treated, locally advanced or metastatic cholangiocarcinoma. The study included patients with and without FGFR2 fusions or rearrangements.
Paper Details　
Original Abstract of the Article :
Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the pathogenesis of cholangiocarcinoma. Pemigatinib is a selective, potent, oral inhibitor of FGFR1, 2, and 3. This study evaluated the safety and antitumour activity of pemigatinib in patients with previously treated, local...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/32203698

データ提供：米国国立医学図書館（NLM）

Pemigatinib: A New Weapon Against Cholangiocarcinoma

Cancer, with its relentless nature, is a formidable adversary, like a sandstorm that threatens to engulf everything in its path. This study focuses on cholangiocarcinoma, a cancer of the bile ducts, and explores the therapeutic potential of pemigatinib, a drug that targets specific receptors implicated in tumor growth. Pemigatinib, like a cool breeze in the desert, aims to disrupt the signaling pathways that fuel the cancer's growth. The researchers embarked on a clinical trial to evaluate the safety and efficacy of pemigatinib in patients with cholangiocarcinoma.

Pemigatinib Shows Potential in Treating Cholangiocarcinoma

The results of this study, like a well-placed oasis, offer some hope in the fight against cholangiocarcinoma. Pemigatinib demonstrated anti-tumor activity, indicating its potential as a treatment option. This finding, like a camel finding a source of water, suggests a potential path towards treating this challenging cancer. Further research is needed to fully understand the role of pemigatinib in the treatment of cholangiocarcinoma.

The Importance of Targeted Therapy

This study emphasizes the importance of targeted therapies in cancer treatment. Just like a skilled desert navigator can find a route through a treacherous landscape, targeted therapy aims to precisely attack the cancer while minimizing harm to healthy cells. Pemigatinib's potential is a reminder that the desert of cancer research is not barren, but holds the promise of new discoveries and therapies.

Dr.Camel's Conclusion

This study, like a camel caravan venturing through a desert, explores the therapeutic potential of pemigatinib in treating cholangiocarcinoma. While the journey continues, the results offer a glimpse of hope in the fight against this challenging cancer. The potential of pemigatinib highlights the importance of targeted therapies in cancer treatment, reminding us that even in the most challenging landscapes, there is always the possibility of finding a path to healing.
Date :
  1. Date Completed 2020-07-09
  2. Date Revised 2023-09-21
Further Info :

Pubmed ID

32203698

DOI: Digital Object Identifier

NIHMS1699451

Related Literature

Article Analysis
・Side Effects of pemigatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.